Jakob C et al. - Data presented in this study demonstrate that the inclusion of the collagen-I degradation product carboxy-terminal telopeptide of type-1 collagen (ICTP), as a biomarker of bone resorption, in multiple myeloma (MM) patients adds to the prognostic value of International Staging System (ISS). Methods
Study to investigate the prognostic impact of the bone resorption marker ICTP in combination with ISS, β2M, albumin, deletion of chromosome 13 and high-dose therapy (HDT) in 100 MM pts
Results
β2M alone, albumin alone, ISS, HDT, del(13q14) and ICTP were significant prognostic factors for OS
ICTP was the most powerful prognostic factor
ICTP clearly separated two subgroups with a good and a worse prognosis within each of the 3 ISS stages
Incorporation of ICTP in a combined ICTP-ISS score separated 4 risk groups with a 5-yr OS rate of 95, 65, 46 and 32% , respectively
See all
